Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Substantial differences in serum concentrations of psychoactive drugs measured in samples stored for two days or more on standard serum tubes versus serum tubes containing gel separators.

Wollmann BM, Lunde HA, Støten LK, Lunder N, Molden E.

Ther Drug Monit. 2018 Dec 11. doi: 10.1097/FTD.0000000000000592. [Epub ahead of print]

PMID:
30540671
2.

Response: Are thyroid abnormalities only related to antipsychotic treatment in patients with severe mental disorders?

Vedal TSJ, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, Rødevand L, Melle I, Andreassen OA, Molden E, Jönsson EG.

J Psychiatr Res. 2018 Nov 13. pii: S0022-3956(18)31308-6. doi: 10.1016/j.jpsychires.2018.11.012. [Epub ahead of print] No abstract available.

PMID:
30454945
3.

Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study.

Viktil KK, Lehre I, Ranhoff AH, Molden E.

Drugs Aging. 2018 Nov 9. doi: 10.1007/s40266-018-0609-4. [Epub ahead of print]

PMID:
30411284
4.
5.

Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients.

Tveito M, Smith RL, Molden E, Haslemo T, Refsum H, Hartberg C, Correll CU, Høiseth G.

J Clin Psychopharmacol. 2018 Dec;38(6):570-576. doi: 10.1097/JCP.0000000000000961.

PMID:
30300295
6.

Free thyroxine and thyroid-stimulating hormone in severe mental disorders: A naturalistic study with focus on antipsychotic medication.

Vedal TSJ, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, Rødevand L, Melle I, Andreassen OA, Molden E, Jönsson EG.

J Psychiatr Res. 2018 Nov;106:74-81. doi: 10.1016/j.jpsychires.2018.09.014. Epub 2018 Sep 25.

PMID:
30292780
7.

Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients.

Hole K, Heiberg PL, Gjestad C, Mehus LL, Rø Ø, Molden E.

Pharmacol Res Perspect. 2018 Sep 11;6(5):e00430. doi: 10.1002/prp2.430. eCollection 2018 Oct.

8.

Clinically Relevant Effect of UGT1A4*3 on Lamotrigine Serum Concentration Is Restricted to Postmenopausal Women-A Study Matching Therapeutic Drug Monitoring and Genotype Data From 534 Patients.

Smith RL, Haslemo T, Chan HF, Refsum H, Molden E.

Ther Drug Monit. 2018 Oct;40(5):567-571. doi: 10.1097/FTD.0000000000000540.

PMID:
30086088
9.

Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis.

Wollmann BM, Syversen SW, Vistnes M, Lie E, Mehus LL, Molden E.

Drug Metab Dispos. 2018 Oct;46(10):1384-1389. doi: 10.1124/dmd.118.082065. Epub 2018 Jul 10.

PMID:
29991576
10.

Hvem bør få klopidogrel etter hjerneslag?

Ihle-Hansen H, Hagberg G, Molden E, Myrstad M.

Tidsskr Nor Laegeforen. 2018 May 28;138(9). doi: 10.4045/tidsskr.18.0277. Print 2018 May 29. Norwegian. No abstract available.

PMID:
29808656
Free Article
11.

Gjestad et al. reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.

Gjestad C, Haslemo T, Andreassen OA, Molden E.

Br J Clin Pharmacol. 2018 Jul;84(7):1624-1625. doi: 10.1111/bcp.13606. Epub 2018 May 10. No abstract available.

PMID:
29749106
12.

Serumkonsentrasjonsmålinger av DOAK-legemidler.

Dyrkorn R, Lundgaard H, Stokes CL, Molden E, Spigset O.

Tidsskr Nor Laegeforen. 2018 Apr 17;138(7). doi: 10.4045/tidsskr.18.0237. Print 2018 Apr 17. Norwegian. No abstract available.

PMID:
29663756
Free Article
13.

Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker.

Hole K, Wollmann BM, Nguyen C, Haslemo T, Molden E.

Ther Drug Monit. 2018 Aug;40(4):463-468. doi: 10.1097/FTD.0000000000000518.

PMID:
29649093
14.

Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection.

Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, Legge SE, Bishop S, Cameron D, Hamshere ML, Han J, Hubbard L, Lynham A, Mantripragada K, Rees E, MacCabe JH, McCarroll SA, Baune BT, Breen G, Byrne EM, Dannlowski U, Eley TC, Hayward C, Martin NG, McIntosh AM, Plomin R, Porteous DJ, Wray NR, Caballero A, Geschwind DH, Huckins LM, Ruderfer DM, Santiago E, Sklar P, Stahl EA, Won H, Agerbo E, Als TD, Andreassen OA, Bækvad-Hansen M, Mortensen PB, Pedersen CB, Børglum AD, Bybjerg-Grauholm J, Djurovic S, Durmishi N, Pedersen MG, Golimbet V, Grove J, Hougaard DM, Mattheisen M, Molden E, Mors O, Nordentoft M, Pejovic-Milovancevic M, Sigurdsson E, Silagadze T, Hansen CS, Stefansson K, Stefansson H, Steinberg S, Tosato S, Werge T; GERAD1 Consortium:; CRESTAR Consortium:, Collier DA, Rujescu D, Kirov G, Owen MJ, O'Donovan MC, Walters JTR; GERAD1 Consortium; CRESTAR Consortium; GERAD1 Consortium; CRESTAR Consortium.

Nat Genet. 2018 Mar;50(3):381-389. doi: 10.1038/s41588-018-0059-2. Epub 2018 Feb 26.

15.

Correction: Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.

Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O.

PLoS One. 2018 Jan 16;13(1):e0191508. doi: 10.1371/journal.pone.0191508. eCollection 2018.

16.

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.

Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M.

Am J Psychiatry. 2018 May 1;175(5):463-470. doi: 10.1176/appi.ajp.2017.17050550. Epub 2018 Jan 12.

PMID:
29325448
17.

Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015.

Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Sætre E, Molden E, Granas AG, Johannessen SI, Landmark CJ.

Epilepsy Res. 2018 Jan;139:35-42. doi: 10.1016/j.eplepsyres.2017.11.001. Epub 2017 Nov 11.

PMID:
29175562
18.

Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy.

Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES, Jørgensen KN, Melle I, Andreassen OA, Molden E, Jönsson EG.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:263-271. doi: 10.1016/j.pnpbp.2017.11.004. Epub 2017 Nov 7.

PMID:
29122637
19.

Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.

Solhaug V, Molden E.

Scand J Pain. 2017 Oct;17:193-200. doi: 10.1016/j.sjpain.2017.09.009. Epub 2017 Oct 17. Review.

PMID:
29054049
20.

Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study.

Smith RL, Haslemo T, Andreassen OA, Eliasson E, Dahl ML, Spigset O, Molden E.

CNS Drugs. 2017 Nov;31(11):991-997. doi: 10.1007/s40263-017-0469-1.

PMID:
28948574
21.

Recovery of CYP3A Phenotype after Kidney Transplantation.

Hole K, Størset E, Olastuen A, Haslemo T, Kro GB, Midtvedt K, Åsberg A, Molden E.

Drug Metab Dispos. 2017 Dec;45(12):1260-1265. doi: 10.1124/dmd.117.078030. Epub 2017 Sep 19.

22.

Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.

Kringen MK, Chalabianloo F, Bernard JP, Bramness JG, Molden E, Høiseth G.

Ther Drug Monit. 2017 Oct;39(5):550-555. doi: 10.1097/FTD.0000000000000437.

PMID:
28723731
23.

Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.

Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O.

PLoS One. 2017 Jul 14;12(7):e0181082. doi: 10.1371/journal.pone.0181082. eCollection 2017. Erratum in: PLoS One. 2018 Jan 16;13(1):e0191508.

24.

Hvis du skal gjøre det, gjør det riktig!

Solberg DK, Refsum H, Molden E.

Tidsskr Nor Laegeforen. 2017 Jun 26;137(12-13):854. doi: 10.4045/tidsskr.17.0441. Print 2017 Jun 27. Norwegian. No abstract available.

PMID:
28655243
Free Article
25.

Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition.

Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O.

Clin Pharmacol Ther. 2018 Mar;103(3):477-484. doi: 10.1002/cpt.770. Epub 2017 Sep 19.

26.

4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.

Gjestad C, Haslemo T, Andreassen OA, Molden E.

Br J Clin Pharmacol. 2017 Nov;83(11):2398-2405. doi: 10.1111/bcp.13341. Epub 2017 Jul 21.

27.

Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A.

Br J Clin Pharmacol. 2017 Jun;83(6):1357-1358. doi: 10.1111/bcp.13276. Epub 2017 Apr 3. No abstract available.

28.
29.

Psychotropics and weak opioid analgesics in plasma samples of older hip fracture patients - detection frequencies and consistency with drug records.

Waade RB, Molden E, Martinsen MI, Hermann M, Ranhoff AH.

Br J Clin Pharmacol. 2017 Jul;83(7):1397-1404. doi: 10.1111/bcp.13244. Epub 2017 Mar 9.

30.

Changes in drug disposition of lithium during pregnancy: a retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norway.

Westin AA, Brekke M, Molden E, Skogvoll E, Aadal M, Spigset O.

BMJ Open. 2017 Mar 1;7(3):e015738. doi: 10.1136/bmjopen-2016-015738.

31.

The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A.

Br J Clin Pharmacol. 2017 Jul;83(7):1457-1465. doi: 10.1111/bcp.13248. Epub 2017 Feb 27.

32.

Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome.

Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, Johannessen Landmark C.

Epilepsy Res. 2017 Jan;129:125-131. doi: 10.1016/j.eplepsyres.2016.12.001. Epub 2016 Dec 5.

PMID:
28043062
33.

Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A.

Br J Clin Pharmacol. 2017 Jun;83(6):1350-1352. doi: 10.1111/bcp.13188. Epub 2016 Dec 22. No abstract available.

34.

4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.

Wollmann BM, Syversen SW, Lie E, Gjestad C, Mehus LL, Olsen IC, Molden E.

Clin Transl Sci. 2017 Jan;10(1):42-49. doi: 10.1111/cts.12431. Epub 2016 Nov 5.

35.

Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.

Hole K, Gjestad C, Heitmann KM, Haslemo T, Molden E, Bremer S.

Eur J Clin Pharmacol. 2017 Mar;73(3):317-324. doi: 10.1007/s00228-016-2178-y. Epub 2016 Dec 14.

PMID:
27975131
36.

[Safer treatment with serum concentration monitoring of the new anticoagulants?].

Lundgaard H, Dyrkorn R, Stokes CL, Molden E, Spigset O.

Tidsskr Nor Laegeforen. 2016 Oct 11;136(18):1556-1560. eCollection 2016 Oct. Norwegian. No abstract available.

37.

Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.

Smith RL, Haslemo T, Refsum H, Molden E.

Eur J Clin Pharmacol. 2016 Sep;72(9):1099-104. doi: 10.1007/s00228-016-2087-0. Epub 2016 Jun 29.

PMID:
27353638
38.

Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.

Molden E, Waade RB, Hoff M, Haslemo T.

Basic Clin Pharmacol Toxicol. 2016 Nov;119(5):470-475. doi: 10.1111/bcpt.12614. Epub 2016 May 31.

39.

[Genetically determined variation in bioactivation of tamoxifen and clopidogrel].

Solhaug V, Molden E.

Tidsskr Nor Laegeforen. 2016 Mar 15;136(5):434-6. doi: 10.4045/tidsskr.15.0555. eCollection 2016 Mar 15. Norwegian. No abstract available.

40.

Effect of teaching and checklist implementation on accuracy of medication history recording at hospital admission.

Lea M, Barstad I, Mathiesen L, Mowe M, Molden E.

Int J Clin Pharm. 2016 Feb;38(1):20-4. doi: 10.1007/s11096-015-0218-9. Epub 2015 Nov 20.

PMID:
26589204
41.

4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?

Gjestad C, Huynh DK, Haslemo T, Molden E.

Br J Clin Pharmacol. 2016 Feb;81(2):269-76. doi: 10.1111/bcp.12833. Epub 2015 Dec 26.

42.

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.

Mannheimer B, Haslemo T, Lindh JD, Eliasson E, Molden E.

Ther Drug Monit. 2016 Feb;38(1):127-34. doi: 10.1097/FTD.0000000000000251.

PMID:
26418700
43.

Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.

Høiseth G, Haslemo T, Uthus LH, Molden E.

Ther Drug Monit. 2015 Oct;37(5):589-93. doi: 10.1097/FTD.0000000000000183.

PMID:
25565674
44.

Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.

Hermann M, Waade RB, Molden E.

Ther Drug Monit. 2015 Aug;37(4):546-9. doi: 10.1097/FTD.0000000000000169.

PMID:
25565671
45.

Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.

Bakken GV, Molden E, Hermann M.

Ther Drug Monit. 2015 Apr;37(2):256-61. doi: 10.1097/FTD.0000000000000135.

PMID:
25254417
46.

Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.

Waade RB, Hermann M, Moe HL, Molden E.

Eur J Clin Pharmacol. 2014 Aug;70(8):933-40. doi: 10.1007/s00228-014-1696-8. Epub 2014 May 27.

PMID:
24858822
47.

No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.

Söderberg MM, Molden E, Dahl ML.

Pharmacogenet Genomics. 2014 May;24(5):272-5. doi: 10.1097/FPC.0000000000000041.

PMID:
24595013
48.

More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.

Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, Molden E, Reier-Nilsen M, Holdaas H, Midtvedt K.

Transplantation. 2014 Jun 27;97(12):1266-71. doi: 10.1097/01.TP.0000443225.66960.7e.

49.

Anticholinergic activity in cerebrospinal fluid and serum in individuals with hip fracture with and without delirium.

Watne LO, Hall RJ, Molden E, Raeder J, Frihagen F, MacLullich AM, Juliebø V, Nyman A, Meagher D, Wyller TB.

J Am Geriatr Soc. 2014 Jan;62(1):94-102. doi: 10.1111/jgs.12612. Epub 2014 Jan 2.

PMID:
24383557
50.

Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.

Hendset M, Molden E, Knape M, Hermann M.

Ther Drug Monit. 2014 Feb;36(1):80-5. doi: 10.1097/FTD.0000000000000018.

PMID:
24232129

Supplemental Content

Loading ...
Support Center